RedHill Biopharma (RDHL) files Form 6-K with first half 2025 results

Rhea-AI Filing Summary

RedHill Biopharma Ltd. filed a Form 6-K as a foreign private issuer, providing investors with information on its first half of 2025 performance. The filing furnishes a press release on first half 2025 financial results and operational highlights, unaudited condensed consolidated interim financial information as of June 30, 2025, and related management discussion and analysis.

The 6-K is also incorporated by reference into multiple outstanding Form S-8 and Form F-3 registration statements, allowing the newly furnished information to form part of those securities offering documents.

0001553846--12-312025Q2falseRedHill Biopharma Ltd.6-K2025-06-3000015538462025-01-012025-06-300001553846rdhl:ExclusiveLicenseAgreementWithHylorisPharmaceuticalsSaMember2025-02-242025-02-240001553846rdhl:ExclusiveLicenseAgreementWithHylorisPharmaceuticalsSaMemberifrs-full:TopOfRangeMember2025-02-240001553846dei:AdrMember2024-08-202024-08-200001553846dei:AdrMember2023-03-232023-03-230001553846dei:AdrMember2023-03-222023-03-2200015538462025-05-132025-05-130001553846rdhl:DirectorsAndChiefExecutiveOfficerMemberrdhl:IfrsRestrictedStockUnitsRsuMember2025-03-310001553846rdhl:EmployeesAndConsultantsMemberrdhl:IfrsRestrictedStockUnitsRsuMember2025-03-260001553846rdhl:MovantikMember2025-01-012025-06-300001553846rdhl:FairValueOfWarrantsMemberifrs-full:TopOfRangeMemberifrs-full:InterestRateMeasurementInputMember2025-06-300001553846rdhl:FairValueOfWarrantsMemberifrs-full:TopOfRangeMemberifrs-full:HistoricalVolatilityForSharesMeasurementInputMember2025-06-300001553846rdhl:FairValueOfWarrantsMemberifrs-full:BottomOfRangeMemberifrs-full:HistoricalVolatilityForSharesMeasurementInputMember2025-06-300001553846ifrs-full:WarrantsMemberifrs-full:AtFairValueMemberrdhl:StandardDeviationMember2025-06-300001553846ifrs-full:WarrantsMemberifrs-full:AtFairValueMemberifrs-full:InterestRateMeasurementInputMember2025-06-300001553846rdhl:FairValueOfWarrantsMemberifrs-full:TopOfRangeMemberifrs-full:InterestRateMeasurementInputMember2024-06-300001553846rdhl:FairValueOfWarrantsMemberifrs-full:TopOfRangeMemberifrs-full:HistoricalVolatilityForSharesMeasurementInputMember2024-06-300001553846rdhl:FairValueOfWarrantsMemberifrs-full:BottomOfRangeMemberifrs-full:InterestRateMeasurementInputMember2024-06-300001553846rdhl:FairValueOfWarrantsMemberifrs-full:BottomOfRangeMemberifrs-full:HistoricalVolatilityForSharesMeasurementInputMember2024-06-300001553846rdhl:GaelanMedicalTradeLlcMembercountry:AE2025-01-012025-06-300001553846rdhl:TaliciaMember2025-01-012025-06-300001553846rdhl:GaelanMedicalTradeLlcMember2025-01-012025-06-300001553846ifrs-full:MajorOrdinaryShareTransactionsMemberrdhl:AlumniMember2025-09-042025-09-040001553846rdhl:AmericanDepositoryShareMember2025-01-012025-06-3000015538462025-05-142025-05-140001553846ifrs-full:MajorOrdinaryShareTransactionsMemberrdhl:AlumniMember2025-09-040001553846rdhl:AmericanDepositoryShareMember2025-06-300001553846rdhl:EmployeesAndConsultantsMemberrdhl:IfrsRestrictedStockUnitsRsuMember2025-03-262025-03-260001553846rdhl:DirectorsAndChiefExecutiveOfficerMemberrdhl:IfrsRestrictedStockUnitsRsuMember2025-03-012025-03-310001553846rdhl:AmericanDepositoryShareMemberrdhl:AlumniMemberifrs-full:TopOfRangeMember2025-06-200001553846rdhl:HylorisPharmaceuticalsSaMemberifrs-full:GoodsOrServicesTransferredOverTimeMember2025-01-012025-06-300001553846rdhl:HylorisPharmaceuticalsSaMemberifrs-full:GoodsOrServicesTransferredAtPointInTimeMember2025-01-012025-06-300001553846rdhl:HylorisPharmaceuticalsSaMember2025-01-012025-06-300001553846ifrs-full:FinancialLiabilitiesAtFairValueThroughProfitOrLossDesignatedUponInitialRecognitionCategoryMemberrdhl:FairValueOfWarrantsMemberifrs-full:Level3OfFairValueHierarchyMember2025-06-300001553846ifrs-full:FinancialLiabilitiesAtFairValueThroughProfitOrLossDesignatedUponInitialRecognitionCategoryMemberrdhl:FairValueOfWarrantsMemberifrs-full:Level3OfFairValueHierarchyMember2024-12-310001553846ifrs-full:FinancialLiabilitiesAtFairValueThroughProfitOrLossDesignatedUponInitialRecognitionCategoryMemberrdhl:FairValueOfWarrantsMemberifrs-full:Level3OfFairValueHierarchyMember2024-06-300001553846ifrs-full:FinancialLiabilitiesAtFairValueThroughProfitOrLossDesignatedUponInitialRecognitionCategoryMemberrdhl:FairValueOfWarrantsMemberifrs-full:Level3OfFairValueHierarchyMember2023-12-310001553846ifrs-full:IssuedCapitalMember2025-01-012025-06-300001553846ifrs-full:AdditionalPaidinCapitalMember2025-01-012025-06-300001553846ifrs-full:IssuedCapitalMember2024-01-012024-06-300001553846ifrs-full:AdditionalPaidinCapitalMember2024-01-012024-06-300001553846ifrs-full:RetainedEarningsMember2025-01-012025-06-300001553846ifrs-full:RetainedEarningsMember2024-01-012024-06-300001553846rdhl:RebatesAndPatientDiscountProgramsMember2025-01-012025-06-300001553846rdhl:ProductReturnsMember2025-01-012025-06-300001553846rdhl:RebatesAndPatientDiscountProgramsMember2024-01-012024-06-300001553846rdhl:ProductReturnsMember2024-01-012024-06-300001553846ifrs-full:FinancialLiabilitiesAtFairValueThroughProfitOrLossDesignatedUponInitialRecognitionCategoryMemberrdhl:FairValueOfWarrantsMemberifrs-full:Level3OfFairValueHierarchyMember2025-01-012025-06-300001553846ifrs-full:FinancialLiabilitiesAtFairValueThroughProfitOrLossDesignatedUponInitialRecognitionCategoryMemberrdhl:FairValueOfWarrantsMemberifrs-full:Level3OfFairValueHierarchyMember2024-01-012024-06-300001553846ifrs-full:RetainedEarningsMember2025-06-300001553846ifrs-full:IssuedCapitalMember2025-06-300001553846ifrs-full:AdditionalPaidinCapitalMember2025-06-300001553846ifrs-full:RetainedEarningsMember2024-12-310001553846ifrs-full:IssuedCapitalMember2024-12-310001553846ifrs-full:AdditionalPaidinCapitalMember2024-12-310001553846ifrs-full:RetainedEarningsMember2024-06-300001553846ifrs-full:IssuedCapitalMember2024-06-300001553846ifrs-full:AdditionalPaidinCapitalMember2024-06-300001553846ifrs-full:RetainedEarningsMember2023-12-310001553846ifrs-full:IssuedCapitalMember2023-12-310001553846ifrs-full:AdditionalPaidinCapitalMember2023-12-310001553846rdhl:RebatesAndPatientDiscountProgramsMember2025-06-300001553846rdhl:ProductReturnsMember2025-06-300001553846rdhl:RebatesAndPatientDiscountProgramsMember2024-12-310001553846rdhl:ProductReturnsMember2024-12-310001553846rdhl:RebatesAndPatientDiscountProgramsMember2024-06-300001553846rdhl:ProductReturnsMember2024-06-300001553846rdhl:RebatesAndPatientDiscountProgramsMember2023-12-310001553846rdhl:ProductReturnsMember2023-12-3100015538462024-06-3000015538462023-12-3100015538462024-01-012024-06-3000015538462025-06-3000015538462024-12-31iso4217:USDxbrli:sharesiso4217:USDxbrli:sharesxbrli:purerdhl:installment

​

​

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

​

FORM 6-K

​

Report of Foreign Private Issuer

Pursuant to Rule 13a-16 or 15d-16

of the Securities Exchange Act of 1934

​

For the month of September 2025

Commission File No.:001-35773

​

REDHILL BIOPHARMA LTD.

(Translation of registrant’s name into English)

​

21 Ha’arba’a Street, Tel Aviv, 6473921, Israel

(Address of principal executive offices)

​

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.

Form 20-F ☒       Form 40-F ☐

Attached hereto and incorporated by reference herein are the following:

Exhibit 99.1: Registrant’s press release entitled “RedHill Biopharma Announces First Half 2025 Financial Results and Operational Highlights”.

Exhibit 99.2: Registrant’s condensed consolidated interim unaudited financial information as of June 30, 2025, and for the six months then ended.

Exhibit 99.3: Registrant’s Management Discussion and Analysis of First Half 2025 Financial Results.

This Form 6-K is hereby incorporated by reference into the Company’s Registration Statements on Form S-8 filed with the Securities and Exchange Commission on May 2, 2013 (Registration No. 333-188286), on October 29, 2015 (Registration No. 333-207654), on July 25, 2017 (Registration No. 333-219441), on May 23, 2018 (Registration No. 333-225122), on July 24, 2019 (File No. 333-232776), on March 25, 2021 (File No. 333-254692), on May 3, 2021 (File No. 333-255710), on January 11, 2022 (File No. 333-262099), on June 27, 2022 (File No. 333-265845), on June 29, 2023 (File No. 333-273001), on June 20, 2024 (File No. 333-280327) and on March 25, 2025 (File No. 333-286082), and its Registration Statements on Form F-3 filed with the Securities and Exchange Commission on March 30, 2021 (File No. 333-254848), on August 4, 2023 (File No. 333-273709), on October 13, 2023 (File No. 333-274957), as amended, and on August 9, 2024 (File No. 333-281417).

​

​

​

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	REDHILL BIOPHARMA LTD.
	(the “Registrant”)
Date: September 5, 2025	By:	/s/ Dror Ben-Asher
​	Name:	Dror Ben-Asher	​
​	Title:	Chief Executive Officer	​

​

​

​

​

2

FAQ

What does RedHill Biopharma (RDHL) report in this Form 6-K?

RedHill Biopharma’s Form 6-K furnishes materials on its first half 2025 performance. It includes a press release, unaudited condensed consolidated interim financial information as of June 30, 2025, and a management discussion and analysis of those first half 2025 financial results.

Which financial period does RedHill Biopharma’s (RDHL) Form 6-K cover?

The Form 6-K covers RedHill Biopharma’s financial results for the first half of 2025. It includes unaudited condensed consolidated interim financial information as of June 30, 2025, along with a management discussion and analysis focused on that six‑month period.

What exhibits are attached to RedHill Biopharma’s (RDHL) September 2025 Form 6-K?

The Form 6-K attaches three key exhibits: a press release on first half 2025 financial results and operational highlights, unaudited condensed consolidated interim financial information as of June 30, 2025, and a management discussion and analysis of the first half 2025 results.

How is this RedHill Biopharma (RDHL) Form 6-K used in existing registration statements?

The Form 6-K is incorporated by reference into multiple RedHill Biopharma Form S-8 and Form F-3 registration statements. This means the newly furnished financial and narrative information becomes part of those existing securities offering documents for regulatory and disclosure purposes.

Which registration statements does RedHill Biopharma (RDHL) reference in this Form 6-K?

RedHill Biopharma references numerous Form S-8 registration statements filed between 2013 and 2025 and several Form F-3 statements filed between 2021 and 2024. The 6-K is incorporated by reference into each of these listed registration statements.

Who signed RedHill Biopharma’s (RDHL) September 2025 Form 6-K?

The Form 6-K was signed on behalf of RedHill Biopharma Ltd. by Dror Ben-Asher. He signed in his capacity as Chief Executive Officer, acting as the duly authorized signatory for the registrant under the Securities Exchange Act of 1934.